## BMY: Bristol-Myers Squibb Company - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 2.5% below STRENGTH zone (3.0-6.0%); PEG 2.26 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($49.15)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 5, Bearish: 0)

**1. Bristol Myers Squibb Company $BMY Stock Position Raised by Axa S.A.**
- Source: MarketBeat | 20251209T083058 | Somewhat-Bullish | Relevance: 99%
-  Axa S.A. significantly increased its stake in Bristol Myers Squibb (NYSE:BMY) by 47.7% in Q2, bringing its total holdings to 2,746,873 shares valued at approximately $127.2 million. The biopharmaceutical company currently holds a consensus "Hold" rating from analysts with an average price target of $55.25 and offers a 4.8% dividend yield. Bristol Myers Squibb recently surpassed quarterly EPS estimates and provided positive FY2025 EPS guidance, indicating solid financial performance.

**2. Myelofibrosis Market to Expand Significantly by 2034, States DelveInsight Report | Lynk Pharma, Samus Therapeutics, Taiga Biotech, Bristol-Myers Squibb, Sumitomo Pharma Oncology, Keros Therapeutics**
- Source: Barchart.com | 20251209T142845 | Bullish | Relevance: 99%
-  A DelveInsight report projects the Myelofibrosis market to reach $5,368 million by 2034, growing at a CAGR of 9.0% from 2020. The U.S. currently holds the largest market share, with JAKAFI/JAKAVI (ruxolitinib) being the leading therapy. The market expansion is driven by increasing disease prevalence and the launch of new pipeline products.

**3. Bristol Myers Squibb Advances Lymphoma Research with New Targeted Protein Degradation and Cell Therapy Data at ASH 2025**
- Source: PharmiWeb.com | 20251209T003946 | Bullish | Relevance: 99%
-  Bristol Myers Squibb (BMS) is presenting new research at the 67th American Society of Hematology (ASH) Annual Meeting, highlighting advancements in lymphoma treatment. The data includes updates on targeted protein degradation agents like golcadomide and BMS-986458, alongside long-term results for the CAR T cell therapy BreyanziÂ®. These findings demonstrate promising efficacy and durable responses across various lymphoma types, reinforcing BMS's commitment to developing transformative therapies for patients.

**4. Bristol Myers Squibb (BMY) Is Up 5.1% After Expanded Breyanzi MZL Approval Has The Bull Case Changed?**
- Source: Simply Wall Street | 20251209T002246 | Bullish | Relevance: 98%
-  Bristol Myers Squibb (BMY) recently received U.S. FDA approval for its CAR T cell therapy, Breyanzi, to treat relapsed or refractory marginal zone lymphoma, broadening its patient pool and strengthening its cell therapy franchise. This approval, along with similar European expansions, aims to offset revenue pressures from impending patent cliffs on blockbuster drugs like Eliquis and Opdivo. The company's future performance hinges on successful new therapy launches and clinical trial readouts, particularly for Cobenfy.

**5. BioNTech and Bristol Myers Squibb Present First Global Phase 2 Data for PD-L1xVEGF-A Bispecific Antibody Pumitamig Showing Encouraging Efficacy in Advanced Triple-Negative Breast Cancer**
- Source: The Manila Times | 20251209T121609 | Bullish | Relevance: 98%
-  BioNTech and Bristol Myers Squibb announced encouraging interim Phase 2 data for their investigational bispecific antibody pumitamig (BNT327/BMS986545) plus chemotherapy in patients with locally advanced/metastatic triple-negative breast cancer (TNBC). The data showed promising anti-tumor activity and a manageable safety profile across different PD-L1 expression levels, including low or negative cases, which supports the ongoing Phase 3 ROSETTA BREAST-01 trial and suggests a broad pan-tumor potential for pumitamig. Efficacy highlights include a confirmed objective response rate of 61.5% and a disease control rate of 92.3% among efficacy-evaluable patients.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 2, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-04 | Scotiabank | $53 | $45 | +18% |
| 2025-12-02 | Goldman Sachs | $57 | $51 | +12% |
| 2025-11-17 | Citigroup | $45 | $48 | -6% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-04 | Scotiabank | main | Sector Perform |
| 2025-12-02 | Goldman Sachs | main | Neutral |
| 2025-11-17 | Citigroup | main | Neutral |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 7 ($0.00M) |
| Sells | 3 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 41.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 2 |

**Top Holders:**
- Vanguard Group Inc: 9.6% (+0.5%)
- Blackrock Inc.: 8.6% (+1.9%)
- JPMORGAN CHASE & CO: 8.5% (+65.8%)
- State Street Corpora: 4.7% (+2.0%)
- Charles Schwab Inves: 3.6% (+3.2%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_10 improving +3.9% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 2.26 elevated, pricing in significant growth expectations. Quality metrics strong (ROE 34%). Balance sheet: $6.0B free cash flow. Revenue declining -8% YoY, concerning. Analyst sentiment positive (2 raises, avg +15%). Institutional flow bullish (7 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $105.2B |
| Beta | 0.30 |
| 52W Range | $42.52 - $63.33 |
| Short Interest | 1.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.26 |
| Forward P/E | 8.6 |
| Current P/E | 7.9 |
| YoY Growth | -8.4% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -1.4% to 2.5% (+3.9% in 5 days), confirming momentum buildup. Below STRENGTH zone by 0.5pp (needs >3.0% for momentum thesis). MRS_5 at 1.1% confirms short-term momentum alignment. Outperforming sector by 5.9pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 2.50% (CS: 78) | Neutral |
| RSI_14 | 68.5 | Neutral |
| MACD Histogram | 0.39 | Bullish |
| vs SMA20 | 1.064x | Above |
| vs SMA50 | 1.117x | Above |
| vs SMA200 | 1.053x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $51.67
- **Stop Loss:** $49.15 (4.9% risk)
- **Target:** $54.19 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 198
- **Position Value:** $10,230.66
- **Portfolio %:** 10.23%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

### Earnings

**Next:** 2026-02-05 (Est: $1.65)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.52 | $1.63 | +7.6% |
| 2025Q2 | $1.10 | $1.46 | +32.6% |
| 2025Q1 | $1.50 | $1.80 | +19.9% |
| 2024Q4 | $1.47 | $1.67 | +13.8% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_10*